Article (Scientific journals)
Biennial surveillance of Plasmodium falciparum anti-malarial drug resistance markers in Democratic Republic of Congo, 2017 and 2019
Yobi, D.M.; Kayiba, N.K.; Mvumbi, D.M. et al.
2022In BMC Infectious Diseases, 22 (1)
Peer Reviewed verified by ORBi
 

Files


Full Text
6.pdf
Author postprint (1.16 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Anti-malarial; Biennial; Democratic Republic of Congo; Markers; Plasmodium falciparum; Resistance; Surveillance; antimalarial agent; protozoal protein; cross-sectional study; Democratic Republic Congo; drug combination; drug resistance; genetics; human; malaria falciparum; Antimalarials; Cross-Sectional Studies; Democratic Republic of the Congo; Drug Combinations; Drug Resistance; Humans; Malaria, Falciparum; Protozoan Proteins
Abstract :
[en] Background: Because of the loss of chloroquine (CQ) effectiveness, the Democratic Republic of Congo (DRC)’s malaria treatment policy replaced CQ by sulfadoxine–pyrimethamine (SP) as first-line treatment of uncomplicated malaria in 2003, which in turn was replaced by artemisinin-based combination therapies (ACT) in 2005. The World Health Organization (WHO) recommends monitoring of anti-malarial drug resistance every 2 years. The study aimed to provide baseline data for biennial molecular surveillance of anti-malarial drug resistance by comparing data from a study conducted in 2019 to previously published data from a similar study conducted in 2017 in the DRC. Methods: From July to November 2019, a cross-sectional study was conducted in ten sites which were previously selected for a similar study conducted in 2017 across the DRC. P. falciparum malaria was diagnosed by a rapid diagnostic test (RDT) or by microscopy and dried blood samples (DBS) were taken from patients who had a positive test. Segments of interest in pfcrt and pfk13 genes were amplified by conventional PCR before sequencing. Results: Out of 1087 enrolled patients, 906 (83.3%) were PCR-confirmed for P. falciparum. Like in the 2017-study, none of the mutations known to be associated with Artemisinine (ART) resistance in Southeast Asia was detected. However, non-synonymous (NS) mutations with unknown functions were observed among which, A578S was detected in both 2017 and 2019-studies. The overall prevalence of pfcrt-K76T mutation that confers CQ-resistance was 22.7% in 2019-study compared to 28.5% in 2017-study (p-value = 0.069), but there was high variability between sites in the two studies. Like in 2017-study, the pfcrt 72–76 SVMNT haplotype associated with resistance to amodiaquine was not detected. Conclusion: The study reported, within 2 years, the non-presence of molecular markers currently known to be associated with resistance to ART and to AQ in P. falciparum isolated in the DRC. However, the presence of polymorphisms with as-yet unknown functions was observed, requiring further characterization. Moreover, an overall decrease in the prevalence of CQ-resistance marker was observed in the DRC, but this prevalence remained highly variable from region to region. © 2022, The Author(s).
Disciplines :
Laboratory medicine & medical technology
Author, co-author :
Yobi, D.M.;  Department of Basic Sciences, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic Congo
Kayiba, N.K.;  School of Public Health & Research Institute of Health and Society, Catholic University of Louvain, Brussels, 1200, Belgium, School of Public Health, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic Congo, Department of Public Health, Faculty of Medicine, University of Mbujimayi, Mbuji-Mayi, Democratic Republic Congo
Mvumbi, D.M.;  Department of Basic Sciences, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic Congo
BOREUX, Raphaël ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de microbiologie clinique
Kabututu, P.Z.;  Department of Basic Sciences, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic Congo
Akilimali, P.Z.;  School of Public Health, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic Congo
Situakibanza, H.N.T.;  Department of Internal Medicine, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic Congo
De Mol, Patrick ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques
Speybroeck, N.;  School of Public Health & Research Institute of Health and Society, Catholic University of Louvain, Brussels, 1200, Belgium
Mvumbi, G.L.;  Department of Basic Sciences, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic Congo
Hayette, Marie-Pierre ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de microbiologie clinique
Language :
English
Title :
Biennial surveillance of Plasmodium falciparum anti-malarial drug resistance markers in Democratic Republic of Congo, 2017 and 2019
Publication date :
2022
Journal title :
BMC Infectious Diseases
eISSN :
1471-2334
Publisher :
BioMed Central Ltd
Volume :
22
Issue :
1
Peer reviewed :
Peer Reviewed verified by ORBi
Funding text :
This study was supported by the Académie de Recherche et d'Enseignement Supérieur (ARES), Belgium. The funding body had no role in the study design, interpretation of data and in writing and publication of the manuscript.
Available on ORBi :
since 24 October 2022

Statistics


Number of views
38 (1 by ULiège)
Number of downloads
12 (0 by ULiège)

Scopus citations®
 
3
Scopus citations®
without self-citations
3
OpenCitations
 
1

Bibliography


Similar publications



Contact ORBi